Dr. Lonial on Treating Early Relapse in Multiple Myeloma

Sagar Lonial, MD, FACP
Published: Tuesday, Nov 12, 2019



Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the management of patients with relapsed multiple myeloma. 

Patients with early relapse will progress on one prior line of therapy, says Lonial. However, patient outcomes in this space have improved dramatically over the past 10 years.
 
Notably, some patients with early relapse may experience a remission duration that is as long as their original remission, explains Lonial. This is due, in part, to the availability of agents such as daratumumab (Darzalex), carfilzomib (Kyprolis), and pomalidomide (Pomalyst).
SELECTED
LANGUAGE


Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the management of patients with relapsed multiple myeloma. 

Patients with early relapse will progress on one prior line of therapy, says Lonial. However, patient outcomes in this space have improved dramatically over the past 10 years.
 
Notably, some patients with early relapse may experience a remission duration that is as long as their original remission, explains Lonial. This is due, in part, to the availability of agents such as daratumumab (Darzalex), carfilzomib (Kyprolis), and pomalidomide (Pomalyst).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x